CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $2.22M, lower than 95% of all stocks globally
- PositionGross margin is -21%, lower than 95% of its Biotechnology peers (median 67.1%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
704.47BKRW498.80M · vs all stocks (USD)
Revenue (TTM)
3.13BKRW2.22M · vs all stocks (USD)
Beta
0.8620xvs all stocks
52-Week Change
46.12%vs all stocks
Market Capitalization
704.47BKRW498.80M · vs all stocks (USD)
Enterprise Value
750.27BKRW531.22M · vs all stocks (USD)
Price to Book (MRQ)
6.15xvs Biotechnology peers
Enterprise to Revenue
239.46xvs Biotechnology peers
Enterprise to EBITDA
-43.67xvs Biotechnology peers
Gross Margin
-21.05%vs Biotechnology peers
Operating Margin
-1436.91%vs Biotechnology peers
Return on Assets (TTM)
-8.54%vs Biotechnology peers
Return on Equity (TTM)
-18.55%vs Biotechnology peers
Revenue (TTM)
3.13BKRW2.22M · vs all stocks (USD)
Revenue per Share (TTM)
32.59KRWUpdated Aug 19, 2026Quarterly Revenue Growth
-54.20%vs Biotechnology peers
Gross Profit (TTM)
-269.17MKRW-190.58K · vs all stocks (USD)
EBITDA (TTM)
-17.18BKRW-12.16M · vs all stocks (USD)
Net Income (TTM)
-21.28BKRW-15.07M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-54.19%vs Biotechnology peers
Operating Cash Flow (TTM)
-15.69BKRW-11.11M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-29.29BKRW-20.74M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.52BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
3.27BKRWFY2025 · Dec 31, 2025Gross Profit
243.63MKRWFY2025 · Dec 31, 2025Operating Income
-18.16BKRW-12.86M · vs all stocks (USD)
Pre-tax Income
-22.10BKRWFY2025 · Dec 31, 2025Income Tax Expense
3.89MKRWFY2025 · Dec 31, 2025Net Income
-22.13BKRWFY2025 · Dec 31, 2025EBIT
-19.67BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-19.74BKRWFY2025 · Dec 31, 2025Research & Development
7.60BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
5.44BKRWFY2025 · Dec 31, 2025Other Operating Expenses
367.31MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
1.33BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.43BKRWFY2025 · Dec 31, 2025EPS (Basic)
-0.2100KRWFY2025 · Dec 31, 2025EPS (Diluted)
-0.2100KRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-22.13BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-24.16BKRWFY2025 · Dec 31, 2025Free Cash Flow
-25.35BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
22.34BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-22.13BKRWFY2025 · Dec 31, 2025Stock-based Compensation
22.60MKRWFY2025 · Dec 31, 2025Other Non-cash Items
477.06MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.09BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-438.52MKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.19BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-19.00BKRWFY2025 · Dec 31, 2025Net Acquisitions
-1.81BKRWFY2025 · Dec 31, 2025Purchase of Investments
-30.18BKRWFY2025 · Dec 31, 2025Sale of Investments
12.15BKRWFY2025 · Dec 31, 2025Other Investing Activity
1.23BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-19.80BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
14.85BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-23.97BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-5.00BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
70.13BKRWFY2025 · Dec 31, 2025Shares Outstanding
96.50MSharesUpdated Aug 19, 2026Float Shares
84.88MSharesUpdated Aug 19, 2026% Held by Insiders
10.19%vs all stocks
% Held by Institutions
8.04%vs all stocks
Total Cash (MRQ)
37.80BKRW26.76M · vs all stocks (USD)
Total Cash per Share (MRQ)
393.17KRWUpdated Aug 19, 2026Total Debt (MRQ)
15.09BKRW10.69M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1348xvs Biotechnology peers
Current Ratio (MRQ)
2.40xvs Biotechnology peers
Book Value per Share (MRQ)
1.16KKRWUpdated Aug 19, 2026Total Assets
130.74BKRW92.57M · vs all stocks (USD)
Total Current Assets
43.99BKRWFY2025 · Dec 31, 2025Total Liabilities
20.01BKRWFY2025 · Dec 31, 2025Total Non-current Assets
86.75BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
491.57MKRWFY2025 · Dec 31, 2025Total Current Liabilities
19.52BKRWFY2025 · Dec 31, 2025Cash Equivalents
22.34BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
22.34BKRWFY2025 · Dec 31, 2025Other Short-term Investments
17.74BKRWFY2025 · Dec 31, 2025Accounts Receivable
2.32BKRWFY2025 · Dec 31, 2025Inventory
1.14BKRWFY2025 · Dec 31, 2025Accounts Payable
498.72MKRWFY2025 · Dec 31, 2025Short-term Debt
17.71BKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.55MKRWFY2025 · Dec 31, 2025Long-term Debt
70.44MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-100.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
48.02BKRWFY2025 · Dec 31, 2025Retained Earnings
-41.69BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
110.73BKRW78.40M · vs all stocks (USD)
Treasury Stock
4.04MKRWFY2025 · Dec 31, 202552-Week Low
4.57KKRWUpdated Aug 19, 202652-Week High
21.50KKRWUpdated Aug 19, 202652-Week Change
46.12%vs all stocks
Beta
0.8620xvs all stocks
50-Day MA
7.54KKRWUpdated Aug 19, 2026200-Day MA
9.40KKRWUpdated Aug 19, 2026Avg 10-Day Volume
1.19MSharesUpdated Aug 19, 2026Avg 30-Day Volume
967.85KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.2100KRWUpdated Aug 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -21%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: -0.21Industry median: 0.67Industry P5: 0.14Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $2.22M, lower than 95% of all stocks globallySignificant
Revenue (USD): 2,218,467.27Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Succeeder Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ZJ Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Huaren Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
OrthoPediatrics Corp.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shen Lian Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sd Biosensor Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Valneva SE
Tier 1ProductionApproval-Gated PipelineRuleRisk
ProKidney Corp
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Hunan Yujing Machinery Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Shanghai Fudan Microelectronics Group Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline